



TECO DIAGNOSTICS

1268 N. Lakeview Ave.
Anaheim, CA 92807
1-800-222-9880

URIC ACID ENZYMATIC METHOD TC MATRIX

INTENDED USE



For the quantitative determination of uric acid in serum or plasma on TC Matrix analyzers.

SUMMARY AND EXPLANATION OF THE TEST

Uric acid is the end-product of urine metabolism in humans. It circulates and is filtered from the blood by the glomeruli. The determination of serum uric acid for detecting hyperuricemia is helpful in the diagnosis of gout, increased metabolism of nucleoproteins such as in leukemia and polycythemia. Serum uric acid levels also increase with decreased renal function, diabetic ketosis, shock, alcoholism and starvation.

Uric Acid is converted by uricase into allantoin and hydrogen peroxides. The hydrogen peroxide initiates the coupling of 4-aminoantipyrine to 3,5-dichloro-2-hydroxybenzene sulfonic acid (DHBS) to form the chromogen, which is measured at 520nm and which is proportional to the amount of hydrogen peroxide generated from uric acid.

The TC Matrix System automatically proportions the appropriate sample and reagent volumes into the cuvette. The system monitors the change in absorbance at 520 nanometers. This change in absorbance is directly proportional to the concentration of uric acid in the sample and is used by the TC Matrix System to calculate and express the uric acid concentration.



REAGENT CONTENTS:

Each kit contains: Six Uric Acid Reagent (6x40 ml)

Instruction Insert.

REAGENT PREPARATION

No preparation is required.

REAGENT COMPOSITION

Uricase: 240u/L

4-Aminoantipyrine: 0.85mmol/L

3,5-dichloro-2-hydroxybenzene sulfonate (DHBS): 3.4mmol/L

Horseshoe peroxidase: 960 IU/L

Also non-reactive chemicals for optimal system performance.

REAGENT STORAGE AND STABILITY

Unopened Uric Acid Reagent, stored at 2°C to 8°C, is stable until the expiration date showed on the bottle label. Once opened, Uric Acid Reagent is stable for 21 days, unless the expiration date is exceeded.
DO NOT FREEZE.

SPECIMEN COLLECTION AND HANDLING

1. The test can be performed on serum and plasma. For serum, blood is drawn into a tube which does not contain anticoagulant and allow clotting. The serum is then separated from the clot. A maximum limit of two hours from the time of collection is recommended.
2. Separated serum or plasma should not remain at room temperature longer than 8 hours. If assays are not completed within 8 hours, serum and plasma should be stored at 2°C to 8°C. If assays are not completed within 48 hours, or the separated sample is to be stored beyond 48 hours, samples should be frozen at -15°C to -20°C. Frozen samples should be thawed only once. Analyte deterioration may occur in samples that are repeatedly frozen and thawed.
3. For plasma, add whole blood directly into a tube containing anticoagulant. Acceptable anticoagulants are listed in the "LIMITATIONS" section.

CALIBRATION

1. Calibrator required: TECO MULTI Calibrator.
2. The system must have a valid calibration in memory before controls or patient samples can be run.
3. The TC Matrix system will automatically perform checks on the calibration and produce data at the end of calibration.

Note: Refer to the TC Matrix manual for further instructions on calibrating the instrument

MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT

TECO MULTI Calibrator

At least two levels of control material.

LIMITATIONS

1. The anticoagulants EDTA, Potassium Oxalate, Sodium Fluoride and Sodium Citrate were found to be incompatible with this method.
2. The anticoagulants Ammonium Heparin, Lithium Heparin and Sodium Heparin were found to be compatible with this method.

INTERFERENCE

1. Bilirubin and ascorbic acid can result in falsely depressed uric acid levels.
2. Lipemic samples may cause falsely elevated uric acid levels.
3. Collection tubes containing formaldehyde as a preservative must be avoided.
4. On this method, refer to the work of Young¹⁰ for a review of drug and comprehensive list of substances effect on Uric Acid level.

EXPECTED VALUE

2.6 to 7.2 mg/dL or 155 to 428 μmol/L

PRECAUTIONS

1. For in vitro diagnostic use only.
2. Since all specimens are potentially infectious, they should be handled with appropriate precautions and practices in accordance with Biosafety level 2 as recommended by USA NIH manual Biosafety in Microbiological and Biomedical Laboratories, and in accordance with National or local regulations related to the safety precautions of such materials.
3. Each laboratory has to perform the quality control test to assure the results being reliable before running the specimen tests.

PROCEDURES

TEST NAME:	UA	R1:	200
TEST NO.		R2:	0
FULL NAME:	Uric Acid	SAMPLE VOLUME:	4
REFERENCE NO.:		RI BLANK:	/
ANALY TYPE:	Endpoint	MIX REAG. BLANK:	0.1 - 1.5
PRI. WAVE:	510 nm	CONCENTRATION:	/
SECON. WAVE:	/	LINEARITY LIMIT:	0.5 - 15
TREND:	Increase	SUBSTRATE LIMIT:	/
REACT. TIME:	0 - 40	FACTOR:	/
INCUBATE TIME:	/	PROZONE CHECK:	/
UNIT:	mg/dl	Q1: / Q2: / Q3: / Q4: /	
PRECISION:	0.1	PC: / ABS: /	
Calibration Type: Calibrate+ Reag Blank		Calibration Rule: Two-point linear	

PERFORMANCE CHARACTERISTICS

Analytical Range: 0.5- 15.0 mg/dL

For uric acid analyte by Uric Acid Reagent on TC Matrix System, this method has been demonstrated to be linear from 0.5-15.0 mg/dL

Accuracy: Comparison study was performed on TC Matrix System from 40 samples. Beckman Coulter Uric Acid Reagent was used to compare with Uric Acid Reagent. The results of this study in yield a correlation coefficient of 0.98 with a regression equation of $y=0.95X + 1.2$.

Precision: Within Run precision for Uric Acid Reagent Set was determined following a modification of NCCLS EP5-A. Two commercial human serum were assayed on Beckman CX System for 25 times.

Sample	Sample 1	Sample 2
N	25	25
Mean (mg/dl)	5.9	9.7
Standard Deviation (mg/dl)	0.17	0.22
Coefficient of Variation (%)	3.0	2.1

Run-Day precision for Uric Acid Reagent was determined following a modification of NCCLS EP5-A. Two commercial human serum were assayed on TC Matrix Systems five times per day for five days for the total of 25 values.

Sample	Sample 1	Sample 2
N	25	25
Mean (mg/dl)	5.9	9.7
Standard Deviation (mg/dl)	0.17	0.19
Coefficient of Variation (%)	3.1	2.3

REFERENCES:

1. Fossati, P. Et.al. 1980. Clin.Chem.26:227.
2. Henry R.J.1968. Clin. Chem.: Principles and Technical. 2nd ed. Harper & Row, Hagerstown, MD
3. Tietz, N.W., " Specimen Collection and Processing; Sources of Biological Variation," Textbook of Clinical Chemistry, 2nd Edition, W.B. Saunders, Philadelphia, PA (1994)
4. National Committee for Clinical Laboratory Standards. Approved Guideline, NCCLS publication C28-A, Villanova, PA (1994)
5. Henry, J. B., ed., Clinical Diagnostics and Management by Laboratory Methods, 18th Edition, W.B. Saunders, Philadelphia.
6. Tietz, N.W., ed., Clinical Guide to Laboratory Tests, 2nd Edition, W.B. Saunders, Philadelphia, PA (1990)
7. National Committee for Clinical Laboratory Standards, Method Comparison and Bias Estimation Using Patient Samples; Tentative Guideline, NCCLS Publication EP9-T, Villanova, PA (1993)
8. National Committee for Clinical Laboratory Standards, Precision Performance of Clinical Chemistry Devices; Tentative Guideline, 2nd Edition, NCCLS publication EP5-T2, Villanova, PA (1992)
9. National Committee for Clinical Laboratory Standards, National Evaluation Protocols for Interference Testing, Evaluation Protocol Number 7, Vol. 4, No, June 1984.
10. Young, D.S., Effects of Drugs on Clinical Laboratory Tests, 3rd Ed., AACC Press, Washington DC, 1990, 3-104 thru 3-106.

U582-1170TM: 12/2015



TECO DIAGNOSTICS
1268 N. LAKEVIEW AVE.
ANAHEIM, CA 92807
U.S.A.